What is the treatment for myocarditis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Myocarditis

The treatment of myocarditis should primarily consist of guideline-directed heart failure therapy, complete physical rest for 3-6 months, and avoidance of NSAIDs, with immunosuppression reserved only for specific subtypes such as giant cell, cardiac sarcoidosis, or eosinophilic myocarditis. 1, 2

Diagnostic Approach

Before initiating treatment, proper diagnosis is essential:

  1. Initial testing should include:

    • ECG
    • High-sensitivity cardiac troponin
    • Transthoracic echocardiogram
    • Cardiac MRI (in hemodynamically stable patients) 1
  2. Endomyocardial biopsy (EMB) indications:

    • Patients requiring inotropic support or mechanical circulatory support
    • Patients with Mobitz type 2 second-degree or higher heart block
    • Sustained or symptomatic ventricular tachycardia
    • Failure to respond to guideline-based therapy 1

Treatment Algorithm

1. Acute Management Based on Severity

Mild to Moderate Myocarditis:

  • Hospitalization at an advanced heart failure center 1
  • Supportive care with cardiac monitoring
  • Guideline-directed heart failure medications:
    • Beta-blockers for hemodynamically stable patients
    • ACE inhibitors/ARBs for reduced ejection fraction
    • Low-dose aldosterone antagonists for mildly reduced LV function 2

Fulminant/Severe Myocarditis:

  • Management at centers with expertise in advanced heart failure
  • Consider mechanical circulatory support (including V-A ECMO) for cardiogenic shock 1, 2
  • Inotropic support as appropriate for hemodynamic instability 3

2. Specific Treatments Based on Etiology

Viral Myocarditis:

  • Generally supportive care only
  • Individual trials and meta-analyses suggest immunosuppression is NOT indicated for acute lymphocytic myocarditis in adults 1

COVID-19 Related Myocarditis:

  • Corticosteroids for patients with concurrent COVID-19 pneumonia requiring oxygen 1, 2
  • Intravenous corticosteroids may be considered for hemodynamic compromise or MIS-A 1

Immune-Related Myocarditis (IR-myocarditis):

  • Interrupt immune checkpoint inhibitor therapy
  • Intravenous methylprednisolone 500-1000mg daily for 3 days
  • If troponin falls to <50% of peak level after 3 days, convert to oral prednisolone 1mg/kg/day (max 80mg/day), reducing by 10mg/week 1

Special Subtypes:

  • For giant cell myocarditis, cardiac sarcoidosis, or eosinophilic myocarditis: immunosuppressive therapy is indicated 1, 2

3. Medications to Avoid

  • NSAIDs should be strictly avoided due to risk of increased inflammation and mortality 1, 2
  • Exception: For patients with suspected pericardial involvement, NSAIDs, colchicine, and/or prednisone may be reasonable 1

Follow-up and Recovery

  1. Exercise Restriction:

    • Complete abstinence from competitive sports and strenuous exercise for 3-6 months 1, 4
    • Sustained aerobic exercise during acute viral myocarditis leads to increased mortality in animal models and can lead to sudden death 1
  2. Surveillance Testing (3-6 months after presentation):

    • ECG
    • Echocardiogram
    • Ambulatory rhythm monitor
    • Cardiac MRI 2
  3. Return to Activity Criteria:

    • Absence of cardiopulmonary symptoms
    • Resolution of laboratory evidence of myocardial injury
    • Normalization of LV systolic function
    • Absence of spontaneous/inducible cardiac arrhythmias on ECG monitoring and exercise stress testing 1

Prognosis and Complications

  • Approximately 75% of patients admitted with myocarditis have an uncomplicated course with mortality rate of approximately 0% 3
  • Acute myocarditis complicated by heart failure or ventricular arrhythmias is associated with a 12% rate of in-hospital mortality or need for heart transplant 3
  • Patients with hemodynamic instability have approximately 28% rate of mortality or heart transplant at 60 days 3

Common Pitfalls to Avoid

  • Inappropriate use of NSAIDs worsening inflammation and increasing mortality 1, 2
  • Premature return to strenuous activity leading to sudden death 2
  • Indiscriminate use of immunosuppression for viral myocarditis 1, 2
  • Overuse of beta-blockers in patients with compromised cardiac function potentially precipitating cardiogenic shock 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Managing Atrial Fibrillation and Myocarditis during COVID-19 Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.